PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Bought by Americana Partners LLC

Americana Partners LLC lifted its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 26.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,525 shares of the company's stock after acquiring an additional 4,875 shares during the period. Americana Partners LLC's holdings in PROCEPT BioRobotics were worth $1,894,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in PRCT. Rhumbline Advisers grew its stake in PROCEPT BioRobotics by 5.6% during the 4th quarter. Rhumbline Advisers now owns 61,296 shares of the company's stock worth $4,936,000 after buying an additional 3,242 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in PROCEPT BioRobotics by 218.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 401,210 shares of the company's stock worth $33,350,000 after buying an additional 275,071 shares during the last quarter. Matisse Capital grew its stake in PROCEPT BioRobotics by 112.9% during the 4th quarter. Matisse Capital now owns 22,285 shares of the company's stock worth $1,794,000 after buying an additional 11,817 shares during the last quarter. Chicago Capital LLC grew its stake in PROCEPT BioRobotics by 44.5% during the 4th quarter. Chicago Capital LLC now owns 379,582 shares of the company's stock worth $30,564,000 after buying an additional 116,931 shares during the last quarter. Finally, KBC Group NV grew its stake in PROCEPT BioRobotics by 46.0% during the 4th quarter. KBC Group NV now owns 2,236 shares of the company's stock worth $180,000 after buying an additional 705 shares during the last quarter. 89.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on PRCT shares. Morgan Stanley started coverage on PROCEPT BioRobotics in a research note on Monday, December 2nd. They set an "overweight" rating and a $105.00 target price on the stock. Truist Financial reiterated a "buy" rating and set a $105.00 price target (up previously from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, October 30th. Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They set a "hold" rating and a $95.00 price target on the stock. Finally, Wells Fargo & Company reiterated an "overweight" rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and a consensus target price of $97.86.

Insider Activity

In other news, CEO Reza Zadno sold 26,423 shares of the business's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the completion of the transaction, the chief executive officer now owns 152,762 shares of the company's stock, valued at $14,851,521.64. The trade was a 14.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Alaleh Nouri sold 28,092 shares of the business's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares of the company's stock, valued at approximately $5,096,605.36. This trade represents a 34.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 80,935 shares of company stock valued at $7,882,089 in the last quarter. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock traded down $3.14 during trading hours on Friday, hitting $62.25. 1,465,542 shares of the stock traded hands, compared to its average volume of 861,542. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of -31.92 and a beta of 1.03. The firm's 50 day moving average price is $76.53 and its 200-day moving average price is $79.72. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a 1 year low of $45.20 and a 1 year high of $103.81.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).